Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

FoundationOne

ESMO Patient Centricity Highlights from Dr. Whyte

During #ESMO22 we brought together a panel of world-renowned experts, including WebMD CMO John Whyte, Professor Nadia Harbeck, MD, PhD, Lesley Fallowfield DBE, and Steve Clark, patient advocate and campaigns ambassador, Cancer Research UK (CRUK), volunteer...

Medscape Education Global

regeneron headquarters

Regeneron’s Libtayo combination granted FDA approval for non-small-cell lung cancer

The decision was based on superior survival outcomes of Libtayo plus chemotherapy

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

AstraZeneca’s Farxiga shows benefits for heart failure patients in phase 3 trial

The SGLT2 inhibitor improved symptom burden, physical limitations and quality of life

- PMLiVE

Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation

Elranatamab-treated patients achieved an overall response rate of 61% in a phase 2 trial

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives EC approval for prevention of RSV in infants

The decision makes the antibody the first broadly protective option for this age population

- PMLiVE

NHS reports rise in prostate cancer treatments in England

Prostate Cancer UK’s risk checker has been used over a million times since its launch in February

- PMLiVE

AstraZeneca and Medera’s Novoheart develop first human models of heart failure

The ‘heart-in-a-jar’ model will be used to effectively test drug candidates for HFpEF patient

- PMLiVE

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

Vaxzevria has been shown to be effective against all forms of COVID-19

- PMLiVE

AbbVie submits application for lymphoma therapy epcoritamab to EMA

Phase 2 trial showed an overall response rate of 63% and a complete response rate of 39%

- PMLiVE

Alexion’s Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Ultomiris-treated patients showed zero relapses with a median treatment duration of 73 weeks

- PMLiVE

ICR study reveals how cancers can evolve without relying on DNA mutations

The researchers found that epigenetic changes play a key role in how cancers adapt and evolve

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links